stockrow
Saturday 7 November 2026
Export ABSI’s income statement to Excel — free account
Absci Corporation
ABSI Healthcare Biotechnology
Absci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024.
- Revenue
- −46.4%
- EPS
- +12.5%
- Free cash flow
- −71.7%
- Total debt
- −93.0%
Quarter to June 2026, against a year earlier
10.17
0.78
+8.31%
Follow ABSI
Alert me
Absci Corporation (ABSI) P/E ratio
Absci Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABSI Absci Corporation | n/m |
| SLS SELLAS Life Sciences Group, Inc. compare | n/m |
| GENB Generate Biomedicines, Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| NVAX Novavax, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 6.1× |
| BRVE Braveheart Bio, Inc. compare | — |
| LYCA Lycia Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)